Abstract
Aims: To study IOP lowering efficacy and side effect profile of bimatoprost 0.03% versus fixed combination timolol 0.5% and dorzolamide 2%. Settings and Design: Prospective, open, randomized, parallel group, comparative study, 100 patients of POAG/ocular hypertension with moderate glaucomatous damage attending the outpatient department of ophthalmology, at our institute were included. Materials and Methods: The patients were randomly assigned to one of the two treatment groups, each having a sample size of 50 patients. Group 1 instilled 1 drop of Bimatoprost 0.03%at 8 p.m. (once daily) for 12 weeks and Group 2 instilled 1 drop of fixed drug combination of timolol 0.5% and dorzolamide 2% at 8a.m. and 1 drop at 8p.m. for 12 weeks. All the patients were subjected to the detailed ocular examination following examination and tests at baseline, 4 weeks, 8 weeks and 12 weeks after starting the study treatment. Results: Both the groups showed comparable IOP reductions in the patients. There was no statistically significant difference in the mean IOP reduction among the two groups’ at all follow-up visits. The most frequently reported adverse effect was conjunctival hyperaemia in bimatoprost group and burning, stinging sensation in eyes and taste perversion in the DTFC group. Conclusion: Bimatoprost can be used as a long term monotherapy agent in the treatment of POAG and ocular hypertension providing good efficacy with an easy dosing regimen and without much side effects. Keywords: Bimatoprost, Timolol dorzolamide, Primary open angle glaucoma, Ocular hypertension
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call